University of Dundee - Confidence in Concept 2014
Lead Research Organisation:
University of Dundee
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
The Confidence in Concept scheme is a key part of MRC’s translational research strategy and provides annual awards to institutions, to be used flexibly to support the earliest stages of multiple translational research projects. The award can be used by the institution to support a number of preliminary-stage translational projects. The projects supported should aim to provide sufficient preliminary data to establish the viability of an approach –– before seeking more substantive funding. It is intended to accelerate the transition from discovery research to translational development projects by supporting preliminary work or feasibility studies to establish the viability of an approach.
People |
ORCID iD |
Publications
Evans JC
(2021)
Targeting Mycobacterium tuberculosis CoaBC through Chemical Inhibition of 4'-Phosphopantothenoyl-l-cysteine Synthetase (CoaB) Activity.
in ACS infectious diseases
Heap RE
(2017)
Identifying Inhibitors of Inflammation: A Novel High-Throughput MALDI-TOF Screening Assay for Salt-Inducible Kinases (SIKs).
in SLAS discovery : advancing life sciences R & D
Mendes V
(2021)
Inhibiting Mycobacterium tuberculosis CoaBC by targeting an allosteric site.
in Nature communications
Moynié L
(2016)
A Substrate Mimic Allows High-Throughput Assay of the FabA Protein and Consequently the Identification of a Novel Inhibitor of Pseudomonas aeruginosa FabA.
in Journal of molecular biology
| Description | European Lead Factory |
| Amount | £500,000 (GBP) |
| Organisation | European Commission |
| Department | Innovative Medicines Initiative (IMI) |
| Sector | Public |
| Country | Belgium |
| Start | 06/2017 |
| Description | High growth spinout |
| Amount | £131,000 (GBP) |
| Organisation | Scottish Enterprise |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2020 |
| End | 03/2021 |
| Description | MRC |
| Amount | £823,000 (GBP) |
| Funding ID | MR/P000509/1 |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | |
| Description | project grant |
| Amount | £209,048 (GBP) |
| Organisation | Versus Arthritis |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2014 |
| End | 12/2016 |
| Description | project grant |
| Amount | £261,067 (GBP) |
| Organisation | Arch Therapeutics |
| Sector | Private |
| Country | United States |
| Start | 01/2017 |
| End | 12/2019 |
| Description | translational medical research fund 2014 |
| Amount | £18,500 (GBP) |
| Organisation | University of Dundee |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 04/2014 |
| Description | Hit TB TbCoABC sub-project |
| Organisation | Foundation for the National Institutes of Health (FNIH) |
| Country | United States |
| Sector | Charity/Non Profit |
| PI Contribution | Data and assays generated by the CiC supported HTS project. The hit Tb grant (our funded resource from the collaboration) we will support 1 FTE years chemistry and computational chemistry plus purchasing of commercial analogues of the hits. |
| Collaborator Contribution | Structural biology Tb cell biology and animal model work on selected examples. Fragment screening data and assays. |
| Impact | To early to generate defined outputs |
| Start Year | 2015 |
| Description | Investment Partnership Agreement |
| Organisation | Perceptive Bioscience Holdings Ltd |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | The University has signed an Investment Partnership Agreement with Perceptive that will allow the DDU to further translate programmes developed with MRC CiC funding up to preclinical candidates. |
| Collaborator Contribution | Perceptive will underwrite the CURE Fund for up to 10 years. |
| Impact | The investment sum will be disclosed later in the year. |
| Start Year | 2016 |
| Company Name | HepaRegeniX GmbH |
| Description | HepaRegeniX is a biopharmaceutical company focused on the discovery, development and clinical testing of selective and potent MKK4 inhibitors for liver disease and human tissue regeneration. The company, spun out of the University of Tubingen, was registered in January 2016 and has signed a collaboration with the DDU in Dundee where we have developed an screening assay for MKK4 and completed a diversity screen. The group in Germany was introduced to us through Boehringer Ingelheim Venture Fund who were looking for Dundee input to the technology before they committed to funding a spinout. |
| Year Established | 2016 |
| Impact | Heparegenix currently only has a handfull of employees but is expected to have 20 by the year end when full funding has been secured. Dundee will be awarded £154,000 to acquire sole ownership of the Dundee MKK4 data. |
| Website | http://www.recently-registered.com/www/heparegenix.com |